{"id":516443,"date":"2010-04-05T15:59:17","date_gmt":"2010-04-05T19:59:17","guid":{"rendered":"http:\/\/www.xconomy.com\/?p=71804"},"modified":"2010-04-05T15:59:17","modified_gmt":"2010-04-05T19:59:17","slug":"kineta-nabs-600k-nih-grant","status":"publish","type":"post","link":"https:\/\/mereja.media\/index\/516443","title":{"rendered":"Kineta Nabs $600K NIH Grant"},"content":{"rendered":"\n<div style=\"text-transform:uppercase\"><a href=\"http:\/\/www.xconomy.com\/tag\/Biotech\/\">Biotech<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/autoimmune\/\">Autoimmune<\/a>, <a href=\"http:\/\/www.xconomy.com\/tag\/deals\/\">deals<\/a><\/div>\n<p>\t\t<strong>Luke Timmerman wrote:<\/strong><\/p>\n<p>Kineta, the Seattle-based developer of treatments for autoimmune diseases, <a href=\"http:\/\/www.kinetabio.com\/press_releases\/PressRelease03292010.pdf\">said<\/a> it has received a two-year, $600,000 grant from the National Institutes of Health to do work that could enable clinical trials of a new drug for Type 1 diabetes, multiple sclerosis and other autoimmune diseases. Kineta said it plans to start clinical trials on the drug in the second half of 2010.<\/p>\n<div class=\"postFooter\"><a href=\"http:\/\/www.xconomy.com\/seattle\/2010\/04\/05\/kineta-nabs-600k-nih-grant\/#comments\">Comments<\/a> | <a href=http:\/\/www.xconomy.com\/reprints\/>Reprints<\/a> | Share: &nbsp;<br \/>\n<a href=\"http:\/\/twitter.com\/home?status=RT%20@Xconomy%20Kineta%20Nabs%20$600K%20NIH%20Grant%20http:\/\/xconomy.com\/?p=71804\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/twitter.gif\" alt=\"Retweet\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/www.facebook.com\/sharer.php?u=http:\/\/www.xconomy.com\/seattle\/2010\/04\/05\/kineta-nabs-600k-nih-grant\/&#038;t=Kineta%20Nabs%20$600K%20NIH%20Grant\"  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/facebook.gif\" alt=\"Facebook\"\/><\/a><br \/>\n&nbsp;<a href=http:\/\/www.xconomy.com\/seattle\/2010\/04\/05\/kineta-nabs-600k-nih-grant\/email\/  rel=\"nofollow\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/email.gif\" alt=\"Email\"\/><\/a><br \/>\n&nbsp;<a href=\"http:\/\/sharethis.com\/item?publisher=bfda184d-6684-4f7a-a23f-ca4ed4db9287&amp;title=Kineta+Nabs+%24600K+NIH+Grant&amp;url=http%3A%2F%2Fwww.xconomy.com%2Fseattle%2F2010%2F04%2F05%2Fkineta-nabs-600k-nih-grant%2F\"><img decoding=\"async\" src=\"http:\/\/www.xconomy.com\/wordpress\/wp-content\/themes\/xconomy\/images\/share.gif\" alt=\"Share\"\/><\/a>\n<\/div>\n<p>\n\t\t\t<a href='http:\/\/d1.openx.org\/ck.php?bannerid=' ><br \/>\n\t\t\t<img src='http:\/\/d1.openx.org\/avw.php?bannerid=&amp;cb=327' border='0' alt='' \/><\/a><br \/>\n\t\t\t<br \/>\n\t\t\t\t<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<br clear=\"both\" style=\"clear: both;\"\/><br \/>\n<a href=\"http:\/\/ads.pheedo.com\/click.phdo?s=5b974c17d4c194ce2e950b3d9f9262e9&#038;p=1\"><img decoding=\"async\" alt=\"\" style=\"border: 0;\" border=\"0\" src=\"http:\/\/ads.pheedo.com\/img.phdo?s=5b974c17d4c194ce2e950b3d9f9262e9&#038;p=1\"\/><\/a><br \/>\n<!-- foo --><\/p>\n<p><a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/5WHIOxZrcX0O39J8NWicG8f--xA\/0\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/5WHIOxZrcX0O39J8NWicG8f--xA\/0\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><br \/>\n<a href=\"http:\/\/feedads.g.doubleclick.net\/~a\/5WHIOxZrcX0O39J8NWicG8f--xA\/1\/da\"><img decoding=\"async\" src=\"http:\/\/feedads.g.doubleclick.net\/~a\/5WHIOxZrcX0O39J8NWicG8f--xA\/1\/di\" border=\"0\" ismap=\"true\"><\/img><\/a><\/p>\n<p><img loading=\"lazy\" decoding=\"async\" src=\"http:\/\/feeds.feedburner.com\/~r\/Xconomy_Full\/~4\/hSB9RvqKyss\" height=\"1\" width=\"1\"\/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Biotech, Autoimmune, deals Luke Timmerman wrote: Kineta, the Seattle-based developer of treatments for autoimmune diseases, said it has received a two-year, $600,000 grant from the National Institutes of Health to do work that could enable clinical trials of a new drug for Type 1 diabetes, multiple sclerosis and other autoimmune diseases. Kineta said it plans [&hellip;]<\/p>\n","protected":false},"author":1192,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[7],"tags":[],"class_list":["post-516443","post","type-post","status-publish","format-standard","hentry","category-news"],"_links":{"self":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/516443","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/users\/1192"}],"replies":[{"embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/comments?post=516443"}],"version-history":[{"count":0,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/posts\/516443\/revisions"}],"wp:attachment":[{"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/media?parent=516443"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/categories?post=516443"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/mereja.media\/index\/wp-json\/wp\/v2\/tags?post=516443"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}